Tigecycline- A New Tetracycline Derivative for MRSA Infection

  • M N Rema, MD Amala Institute of Medical Science; President, TC Medical Council.
Keywords: Tigecycline, Antibiotic resistance, Irrational use of antibiotics, Broad spectrum antibiotic

Abstract

Introduction: The inevitable consequence of the widespread use of antimicrobial agents has been the emergence of antibiotic-resistant pathogens, fueling an ever-increasing need for new antimicrobial agents.
Methodology: The clinical use and therapeutic effects of the new drug Tigecycline is described.
Result: Tigecycline is an example of a new drug developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was approved by FDA in 2005

Author Biography

M N Rema, MD, Amala Institute of Medical Science; President, TC Medical Council.

Professor & HOD, Department of Pharmacology

Published
2008-12-30
How to Cite
Rema, M. (2008). Tigecycline- A New Tetracycline Derivative for MRSA Infection. Kerala Medical Journal, 1(2), 69-70. https://doi.org/10.52314/kmj.2008.v1i2.109